Fabien MB, Elodie P, Anna S, Addeo P, Meher B. Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report. World J Clin Cases 2023; 11(6): 1372-1378 [PMID: 36926125 DOI: 10.12998/wjcc.v11.i6.1372]
Corresponding Author of This Article
Moinard-Butot Fabien, MD, Doctor, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg 67200, France. f.moinard-butot@icans.eu
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2023; 11(6): 1372-1378 Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1372
Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report
Moinard-Butot Fabien, Poprawa Elodie, Schohn Anna, Pietro Addeo, Benabdelghani Meher
Moinard-Butot Fabien, Poprawa Elodie, Benabdelghani Meher, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France
Schohn Anna, Department of Supportive Care, Institut de cancérologie Strasbourg Europe, Strasbourg 67200, France
Pietro Addeo, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Hôpitaux Universitaires de Strasbourg, Strasbourg 67200, France
Author contributions: Moinard-Butot F and Benabdelghani M Writing original draft preparation; Moinard-Butot F, Poprawa E and Schohn A performed visualization; Moinard-Butot F, Poprawa E, Schohn A, Addeo P and Benabdelghani M writing review and editing; all authors have read and agreed to the published version of the manuscript.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Moinard-Butot Fabien, MD, Doctor, Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg 67200, France. f.moinard-butot@icans.eu
Received: October 29, 2022 Peer-review started: October 29, 2022 First decision: January 12, 2023 Revised: January 17, 2023 Accepted: February 2, 2023 Article in press: February 2, 2023 Published online: February 26, 2023 Processing time: 117 Days and 18.6 Hours
Abstract
BACKGROUND
Gemcitabine is an antimetabolite used in the treatment of pancreatic cancer. One of the side effects of gemcitabine is vascular toxicity. Here, we report the case of a patient treated with gemcitabine who had peripheral vascular disease concomitant with a prolonged antitumor response.
CASE SUMMARY
A 75-year-old man was diagnosed with locally recurrent pancreatic cancer. Partial response was achieved after 9 mo of gemcitabine. At the same time, the patient reported peripheral vascular disease without necrosis. Chemotherapy was suspended, and after one month the Positron Emission Tomography (PET) scan showed locoregional tumor recurrence. Gemcitabine was resumed and partial response was obtained, but peripheral vascular disease occurred.
CONCLUSION
Our results suggest that the appearance of peripheral vascular disease may be related to a prolonged response to gemcitabine.
Core Tip: Gemcitabine is known for vascular side effect. In this case, we report a vascular acrosyndrome that occurred during first-line with Gemcitabine for pancreatic adenocarcinoma. In this case, the patient experienced prolonged tumor response. Immunological phenomena could be responsible for this double effect.
